Alteogen Inc
KOSDAQ:196170

Watchlist Manager
Alteogen Inc Logo
Alteogen Inc
KOSDAQ:196170
Watchlist
Price: 456 500 KRW -12.04% Market Closed
Market Cap: 24.4T KRW

Alteogen Inc
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Alteogen Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Alteogen Inc
KOSDAQ:196170
Revenue
₩158.1B
CAGR 3-Years
64%
CAGR 5-Years
29%
CAGR 10-Years
39%
Celltrion Inc
KRX:068270
Revenue
₩3.7T
CAGR 3-Years
12%
CAGR 5-Years
21%
CAGR 10-Years
23%
SK Bioscience Co Ltd
KRX:302440
Revenue
₩267.5B
CAGR 3-Years
-34%
CAGR 5-Years
8%
CAGR 10-Years
N/A
V
Voronoi Inc
KOSDAQ:310210
Revenue
₩0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Revenue
₩449.8B
CAGR 3-Years
37%
CAGR 5-Years
37%
CAGR 10-Years
30%
A
ABL Bio Inc
KOSDAQ:298380
Revenue
₩94.9B
CAGR 3-Years
109%
CAGR 5-Years
96%
CAGR 10-Years
N/A
No Stocks Found

Alteogen Inc
Glance View

Market Cap
24.4T KRW
Industry
Biotechnology

In the bustling hub of South Korea's biotech industry, Alteogen Inc. has carved out a distinctive niche with its innovative approach to drug development. Founded in 2008, this company has harnessed the power of advanced biotechnology to specialize in the development of biopharmaceuticals, particularly focusing on creating long-acting protein therapeutics and biobetters. Alteogen's flagship technology, ALT-P7, a proprietary platform for producing antibody-drug conjugates, exemplifies how the company blends scientific ingenuity with commercial acumen. By reimagining existing biological drugs known as biobetters, Alteogen leverages its proprietary technologies to improve the efficacy and delivery of these treatments, promising enhanced convenience and therapeutic outcomes for patients. Financially, Alteogen thrives through both strategic partnerships and its own product pipeline. The company secures revenue by licensing its technology platforms to global pharmaceutical giants, thereby earning milestone payments and royalties. Additionally, Alteogen's ongoing research and development efforts continuously expand its portfolio, particularly in biosimilars—biological products highly similar to already-approved reference products. This dual-pronged approach, combining its proprietary biotechnological innovations with robust strategic alliances, positions Alteogen not just as a player but as an innovator in the biopharmaceutical sector, with the potential for significant impact in the realm of chronic disease treatment.

Alteogen Inc Intrinsic Value
HIDDEN
Show

See Also

What is Alteogen Inc's Revenue?
Revenue
158.1B KRW

Based on the financial report for Jun 30, 2025, Alteogen Inc's Revenue amounts to 158.1B KRW.

What is Alteogen Inc's Revenue growth rate?
Revenue CAGR 10Y
39%

Over the last year, the Revenue growth was 74%. The average annual Revenue growth rates for Alteogen Inc have been 64% over the past three years , 29% over the past five years , and 39% over the past ten years .

Back to Top